766
Granisetron hydrochloride (3 mg on days 1, 8, and 15) and dexamethasone (13.2 mg on day 1 and 6.6 mg on days 2, 3, 8, and 15) were used prior to irinotecan administration in both patients.
 ( potential therapeutic event: used ,  both patients: Subject, Granisetron hydrochloride (3 mg on days 1, 8, and 15) and dexamethasone (13.2 mg on day 1 and 6.6 mg on days 2, 3, 8, and 15): Treatment, irinotecan: Treatment, Granisetron hydrochloride: Treatment.Drug, dexamethasone: Treatment.Drug, 3 mg: Treatment.Dosage, 13.2 mg: Treatment.Dosage, 6.6 mg: Treatment.Dosage, on day 1: Treatment.Freq, on days 1, 8, and 15: Treatment.Freq, on days 2, 3, 8, and 15: Treatment.Freq, dexamethasone: Combination.Drug, Granisetron hydrochloride: Combination.Drug) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( potential therapeutic event: used ,  both patients: Subject, Granisetron hydrochloride (3 mg on days 1, 8, and 15) and dexamethasone (13.2 mg on day 1 and 6.6 mg on days 2, 3, 8, and 15): Treatment, irinotecan: Treatment, Granisetron hydrochloride: Treatment.Drug, dexamethasone: Treatment.Drug, 3 mg: Treatment.Dosage, 13.2 mg: Treatment.Dosage, 6.6 mg: Treatment.Dosage, on day 1: Treatment.Freq, on days 1, 8, and 15: Treatment.Freq, on days 2, 3, 8, and 15: Treatment.Freq, dexamethasone: Combination.Drug, Granisetron hydrochloride: Combination.Drug) 